Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.

Members of the International Hearing Society (IHS) are gearing up to celebrate World Hearing Day on March 3, 2025, to raise awareness of hearing healthcare and address the stigma attached to hearing ...

Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...

The additive manufacturing sector continues to show near-limitless potential. Innovations have taken 3D printers from creating customized figurines all the way to printing entire neighborhoods, ...

A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey towards seeing this treatment in the clinic. For this first phase, the aim ...

An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, ...

It's one of the top healthcare stocks in my portfolio. If I didn't already own this biotech stock, I wouldn't hesitate to buy ...

Super Micro Computer, Inc. (SMCI) stock is on an extended bull run and has more than doubled in 2025. The stock is now the ...

That's encouraging, considering that Vertex's current top-selling CF drug Trikafta/Kaftrio raked in revenue of $10.2 billion ...